The Court of Appeals (CA) has denied Sanofi Pasteur’s motion for reconsideration regarding its Dengvaxia dengue vaccine, upholding a previous decision that revoked the vaccine’s certificates of product registration (CPRs) in 2018.
The revocation followed Sanofi’s 2017 disclosure that Dengvaxia posed risks to individuals who had not previously contracted the virus, leading the Philippine government to halt its national vaccination program.
In a resolution dated September 20, the CA dismissed Sanofi’s petition for review, reaffirming the permanent revocation of the CPRs.
Associate Justice Eduardo Ramos Jr. noted that the arguments presented in the motion had already been deemed without merit.
As a result, the ban on Dengvaxia remains in effect.
Source: PhilNews24 | September 26, 2024
SANOFI’S DENGVAXIA APPEAL DISMISSED BY COURT OF APPEALS
Latest from News
The Commission on Higher Education (CHED) will review allegations by Amianan PH that it has failed
The Bureau of Fire Protection (BFP), led by OIC Chief Supt. Wilberto Rico Neil Kwan Tiu,
The Philippine Ports Authority (PPA) reported a decline in passenger traffic at major ports during this
Bacoor City Mayor Strike Revilla ordered the suspension of the business permit and closure of Ahjay
US authorities have offered assistance to the Philippine National Police (PNP) in its investigation of Thomas